Skip to main content

Dave Muoio

By Dave Muoio | 04:08 pm | April 18, 2018
Stockholm, Sweden-based respiratory monitor maker NuvoAir (formerly Pond Healthcare Innovation) has unveiled the newest version of its home-use spirometer.
By Dave Muoio | 12:17 pm | April 18, 2018
Novo Nordisk and San Francisco-based Sempre Health have announced their collaboration on a pilot program that will offer diabetes medications through the latter company’s monetary incentive and SMS-driven prescription refill platform.
By Dave Muoio | 12:52 pm | April 17, 2018
The Travelers Companies announced yesterday that it would be adding new digital resources to improve healthcare and claims access for employee customers who have experienced a workplace injury.
By Dave Muoio | 05:24 pm | April 16, 2018
In a cohort of patients with non-alcoholic fatty liver disease (NAFLD), an online lifestyle modification-focused intervention was similarly effective to a group-based program in achieving weight loss and liver enzyme normalization, according to data from an Italian study recently presented at The International Liver Congress in Paris.
By Dave Muoio | 03:10 pm | April 16, 2018
New York-based in-home senior care technology company Hometeam is shedding two of its top executives as it shifts from a consumer payment-focused business model to one accommodating reimbursement from payers.
By Dave Muoio | 12:06 pm | April 16, 2018
Chicago-based Level Ex has received an undisclosed investment from OSF Ventures, the investment arm of Peoria, Illinois-based 13-hospital system OSF HealthCare.
By Dave Muoio | 04:54 pm | April 12, 2018
Cambridge, Massachusetts-based Common Sensing, which specializes in connected containers for injectable medications, has raised $6.
By Dave Muoio | 03:43 pm | April 12, 2018
Lending an ear.
By Dave Muoio | 12:10 pm | April 12, 2018
The FDA has granted diagnostics company IDx’s De Novo request to market its AI-based software system for the autonomous detection of diabetic retinopathy in adults who have diabetes, called IDx-DR.
By Dave Muoio | 11:04 am | April 12, 2018
ActiGraph activity monitors and a mobile app from Clinical Ink are are at the heart of a newly announced pilot study backed by Bayer, according to a statement released today by ActiGraph.